Broker tips big gains and yields from NIB shares

Goldman Sachs is saying good things about this health insurance provider.

| More on:
A medical specialist holds a red heart connected via technology and artificial intelligence (AI)

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares are ending the week on a positive note.

In late morning trade, the health insurance company's shares are up 0.5% to $7.59.

This latest gain means that its shares are now up over 6% since this time last year.

This compares favourably to a 2.5% decline by the ASX 200 index over the same period.

Can NIB shares keep rising?

Analysts at Goldman Sachs remain positive on the company and see scope for double-digit gains from current levels.

In response to quarterly data released by APRA, the broker has retained its buy rating and $8.40 price target on NIB's shares.

This implies a potential upside of 10.7% for investors over the next 12 months. In addition, the broker is forecasting a 3.8% dividend yield in FY 2024, boosting the total potential return to 14.5%.

It then expects dividend yields of 4.35% in FY 2025 and 4.6% in FY 2026.

What did the broker say?

Goldman believes that the data released by APRA supports is supportive of its positive view on NIB. It notes:

Relative to pre-Covid, we still think trends screen favourably for the health insurers across rate increases v benefit growth per insured life: Over the 12 mths to Sep-23 v pre Covid i.e. 12 mths to Sep-19, we still see positive jaws of underlying rate at an industry level over that period exceeding the growth in benefit per insured life. However, we do see strong benefit growth per insured life over 12 mth to Sep-23 v pcp (from a low base).

Why is it bullish?

Outside the above, there are a number of reasons why Goldman is bullish on NIB shares. The broker explains:

We are Buy-rated on NHF given: 1) it offers defensive exposure to the private health insurance sector which is experiencing favourable operating trends, 2) claims environment remains low with no immediate indications of a bounce back in claims, 3) DCL provisions to cover a bounce back in claims are proving redundant, 4) significant policyholder give back incentives suggest claiming environment remains well below expectations, 5) strong recovery in non-resident volume post Covid-19 through the return of international students, workers and visitor arrivals.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »